Placeholder Banner

BIO Statement on President’s Budget Proposal

March 16, 2017

Washington, DC (March 16, 2017) – BIO Senior Vice President for Communications Kenneth Lisaius issued the following statement today regarding President Trump’s budget blueprint:

“While we are still reviewing today’s budget blueprint, we have initial concerns with the proposed reductions in the budgets for biomedical research, public health, and for agencies that play an important role in promoting innovations in agricultural, environmental, and human health. We are encouraged by other language in the budget blueprint that seeks to improve the regulatory environment for such innovations. As regards to user fee programs, we look forward to working with the President and Congress to preserve the commitments reflected in the carefully negotiated PDUFA VI goals letter, and ensuring that this vital program is reauthorized in a timely manner. We look forward to learning more about the President’s proposals to improve the FDA’s ability to perform its essential public health mission.”

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…